Akso Health Group
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.8M | $14.8M | $2.4M | $13.2M | $6.0M | $1.8M | $6.9M | $3.7M |
| Cost of Revenue | $13.8M | $15.1M | $2.3M | $11.9M | $5.4M | $544.6K | $1.0M | $7.4M |
| Gross Profit | $-11.3K | $-281.5K | $122.1K | $1.3M | $605.1K | $1.8M | $6.9M | $-3.7M |
| Gross Margin | -0.1% | -1.9% | 5.1% | 9.6% | 10.1% | 100.0% | 100.0% | -100.2% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $421.2K | $441.4K | $117.9K | $0 |
| SG&A Expense | $4.0M | $3.6M | $8.6M | $15.5M | $2.7M | $2.0M | $20.5M | $3.1M |
| Operating Income | $-20.7M | $-166.3M | $-8.6M | $-14.3M | $-3.3M | $-4.2M | $-48.1M | $-7.2M |
| Operating Margin | -149.7% | -1,125.4% | -357.8% | -108.2% | -54.3% | -241.7% | -695.7% | -194.6% |
| Interest Expense | — | — | — | — | $804.1K | $2.2M | — | — |
| Pretax Income | $-20.7M | $-166.3M | $-9.1M | $-13.1M | $-4.0M | $-4.3M | $-46.9M | $-6.8M |
| Income Tax Expense | $-2.0M | $-30.8M | $25.0K | $17.5K | $92.8K | $483.0K | $490.0K | $807.7K |
| Net Income | $-18.7M | $-135.0M | $-9.5M | $-1.4M | $-16.9M | $-34.8M | $-71.2M | $5.5M |
| Net Margin | -135.0% | -913.4% | -391.8% | -10.3% | -280.9% | -1,984.5% | -1,029.7% | 149.7% |
| EPS (Basic) | $0.01 | $0.05 | $0.00 | $0.00 | $-0.01 | $-0.02 | $-0.04 | $0.00 |
| EPS (Diluted) | $0.01 | $0.05 | $0.00 | $0.00 | $-0.01 | $-0.02 | $-0.04 | $0.00 |
| Shares Outstanding (Basic) | 2.17B | 2.57B | 2.55B | 2.47B | 2.15B | 1.76B | 1.76B | 1.75B |
| Shares Outstanding (Diluted) | 2.17B | 2.57B | 2.55B | 2.47B | 2.15B | 1.76B | 1.76B | 1.90B |
| Dividends Per Share | — | — | — | — | — | — | — | — |